Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IQ-AI (IQAI)

Price 1.60p on 22-11-2024 at 17:30:02
Change 0.25p 18.52%
Buy 1.70p
Sell 1.50p
Buy / Sell IQAI Shares
Last Trade: Sell 6,330.00 at 1.58p
Day's Volume: 2,227,491
Last Close: 1.60p
Open: 1.35p
ISIN: JE00BD4H0R42
Day's Range 1.35p - 1.60p
52wk Range: 0.975p - 5.15p
Market Capitalisation: £4m
VWAP: 1.5812p
Shares in Issue: 222m

Recent Trades History IQ-AI (IQAI)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 6,330 1.58p Ordinary
16:26:27 - 22-Nov-24
Buy* 10,000 1.70p Ordinary
16:21:45 - 22-Nov-24
Buy* 60,000 1.69p Ordinary
16:19:17 - 22-Nov-24
Buy* 6,191 1.68p Ordinary
16:06:18 - 22-Nov-24
Buy* 5,601 1.68p Ordinary
15:52:19 - 22-Nov-24
Buy* 65,099 1.656p Ordinary
15:36:32 - 22-Nov-24
Buy* 20,000 1.6051p Ordinary
15:24:56 - 22-Nov-24
Sell* 164,000 1.5604p Ordinary
15:24:14 - 22-Nov-24
Buy* 30,818 1.70p Ordinary
15:12:00 - 22-Nov-24
Buy* 59,523 1.67p Ordinary
15:08:40 - 22-Nov-24

Share Price History for IQ-AI

Time period:
to
Date Open High Low Close Volume

Share News for IQ-AI

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

14th Oct 2024 10:05

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price". Read More

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

16th Aug 2024 20:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: IQ-AI subsidiary opens expanded access programme

25th Jun 2024 11:56

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP." Read More

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

14th Jun 2024 14:32

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer. Read More

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

23rd May 2024 21:08

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value8,262.08
Change112.81

Login to your account

Forgot Password?

Not Registered